Health Trials

Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

ConditionsNSCLCNon-small Cell Lung CancerNon-Small Cell Lung Cancer NSCLCNon-Squamous Non Small Cell Lung CancerLung Cancer (NSCLC)Metastatic NSCLC - Non-Small Cell Lung CancerMetastatic Non-Squamous Non-Small Cell Lung Cancer
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorRevolution Medicines, Inc.

About this trial

The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with pembrolizumab and platinum-based chemotherapy doublet compared to placebo in combination with pembrolizumab and platinum-based chemotherapy doublet.

Eligibility criteria

Qualifiers

At least 18 years old and has provided informed consent.

Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Histologically or cytologically confirmed, previously untreated metastatic non-squamous NSCLC.

Known PD-L1 status

Disqualifiers

Prior treatment with systemic anticancer therapy in metastatic setting for NSCLC.

Prior systemic therapy with any RAS-directed therapy.

Untreated (symptomatic or asymptomatic) central nervous system metastatic disease.

Any conditions that may affect the ability to take or absorb study drug.

Trial design

Treatments tested in this trial

  • zoldonrasib
  • Placebo
  • pembrolizumab
  • pemetrexed + cisplatin /carboplatin

Treatment groups

430 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Revolution Medicines, Inc.

Lead sponsor

Source ClinicalTrials.gov